New view on advanced renal cancer targeted therapies efficacy – controversies
Journal Title: OncoReview - Year 2011, Vol 1, Issue 1
Abstract
During the last few years the strong progress on new therapies in advanced/metastatic renal cell carcinoma has been observed. It is mostly related to understanding of significant renal cell cancer molecular basics. Previously, the standard of care for patients with advanced disease was cytokine therapy, such as interleukin-2 (IL-2) or interferon alpha. The efficacy of cytokines therapy is limited and both drugs are associated with significant toxicity. New therapies, called targeted therapies, have been approved based on randomized clinical trials, in accordance with the american Food and Drug Administration agency and the European Medicines Agency directives. Targeted therapies include vascular endothelial growth factor receptor tyrosine kinase inhibitors (sorafenib, sunitinib, pazopanib), monoclonal vascular endothelial growth factor antibodies (bevacizumab) and seronine-threonine kinase mTOR inhibitors (temsirolimus, everolimus) (mTOR, mammalian target of rapamycin). Based on mentioned clinical trials the efficacy of targeted therapies was demonstrated first of all on the basis of significant progression free survival improvement. Until now the gold standard of oncology treatment efficacy was the overall survival. The controversies and most recent reports on mentioned above end points with reference to efficacy results of medications used in advanced/metastatic renal cell cancer treatment are presented in this review.
Authors and Affiliations
Cezary Szczylik
Keywords
Related Articles
- EP ID EP53088
- DOI -
- Views 248
- Downloads 0
Should a diagnosis of cancer impact the anticoagulant therapy in patients with recurrent thromboembolic disease?
Venous thromboembolism often coexists with cancer, deteriorating patient prognosis. The diagnosis of cancer in patients who suffer from venous thromboembolism may lead to changes in the anticoagulant therapy administered...
Zespół rozpadu guza
Zespół rozpadu guza jest stanem zagrożenia życia występującym u pacjentów z rozległymi nowotworami, u których pod wpływem chemioterapii bądź samoistnie dochodzi do masywnego rozpadu komórek nowotworowych z uwolnieniem ic...
Myocardial dysfunction related to trastuzumab therapy – is effective treatment always possible?
Left ventricle systolic dysfunction manifesting during trastuzumab treatment is defined as cardiotoxicity type II. It is characterized by full reversibility after discontinuation of trastuzumab and cardiological pharmaco...
Recommendations for diagnostics and therapy of gastrointestinal stromal tumors (GIST) in 2010
Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of gastrointestinal tract. Advances in the understanding of the molecular mechanisms of GIST pathogenesis have resulted for last years in the...
Follicular mucinosis on the forehead of a 15-year-old girl
Follicular mucinosis is a rare dermatosis characterized by accumulation of mucin in the follicular epithelium and sebaceous glands. Clinically, it is characterized by the presence of papules or well-circumscribed and inf...